{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:31:17Z","timestamp":1790127077768,"version":"4.0.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MED-QUI\/31721\/2017"],"award-info":[{"award-number":["PTDC\/MED-QUI\/31721\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/117586\/2016"],"award-info":[{"award-number":["SFRH\/BD\/117586\/2016"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04138\/2020"],"award-info":[{"award-number":["UIDB\/04138\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04138\/2020"],"award-info":[{"award-number":["UIDP\/04138\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.biopha.2022.114021","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T23:57:52Z","timestamp":1668556672000},"page":"114021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management"],"prefix":"10.1016","volume":"157","author":[{"given":"Jacinta O.","family":"Pinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7649-7418","authenticated-orcid":false,"given":"Mariana","family":"Matias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3515-0781","authenticated-orcid":false,"given":"Vanda","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Eleut\u00e9rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2119-8293","authenticated-orcid":false,"given":"C\u00e9lia","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lurdes","family":"Gano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana D.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduarda","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jesus","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Nuno","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Storm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cec\u00edlia M.P.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Manuela","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.114021_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11912-018-0732-8","article-title":"The world of melanoma: epidemiologic, genetic, and anatomic differences of melanoma across the globe","volume":"20","author":"Dimitriou","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.biopha.2022.114021_bib2","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3390\/nano9101455","article-title":"Emergent nanotechnological strategies for systemic chemotherapy against melanoma","volume":"9","author":"Pinho","year":"2019","journal-title":"Nanomaterials"},{"key":"10.1016\/j.biopha.2022.114021_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112904","article-title":"Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors","volume":"209","author":"Bass","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.114021_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2174\/1389557517666161111110121","article-title":"Recent highlights on molecular hybrids potentially useful in central nervous system disorders","volume":"17","author":"Matias","year":"2017","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.biopha.2022.114021_bib5","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2174\/1381612825666190617155749","article-title":"Anticancer triazenes: from bioprecursors to hybrid molecules","volume":"25","author":"Francisco","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2022.114021_bib6","first-page":"1","article-title":"Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?","author":"Shalini","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.biopha.2022.114021_bib7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2022.114021_bib8","doi-asserted-by":"crossref","first-page":"13861","DOI":"10.1021\/acs.jmedchem.0c01400","article-title":"Platinum(IV)-estramustine multiaction prodrugs are effective antiproliferative agents against prostate cancer cells","volume":"63","author":"Karmakar","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.114021_bib9","first-page":"1","article-title":"Nanoformulations of a Triazene analogue with specific affinity to human melanoma","volume":"1","author":"Calado","year":"2016","journal-title":"J. Nanosci. Adv. Technol."},{"key":"10.1016\/j.biopha.2022.114021_bib10","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1016\/j.bmc.2017.04.049","article-title":"The selective cytotoxicity of new triazene compounds to human melanoma cells","volume":"25","author":"Sousa","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2022.114021_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.phrs.2007.08.003","article-title":"Triazene compounds: mechanism of action and related DNA repair systems","volume":"56","author":"Marchesi","year":"2007","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2022.114021_bib12","series-title":"S.B.T.-C.D.D. and D. Neidle (Ed.), Cancer Drug Des. Discov","first-page":"157","article-title":"Temozolomide: from cytotoxic to molecularly-targeted agent","author":"Stevens","year":"2008"},{"key":"10.1016\/j.biopha.2022.114021_bib13","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acsmedchemlett.1c00252","article-title":"Sulfur analogues of tyrosine in the development of triazene hybrid compounds: a new strategy against melanoma","volume":"12","author":"Granada","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2022.114021_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/chem.201704410","article-title":"Structure and function of human tyrosinase and tyrosinase-related proteins","volume":"24","author":"Lai","year":"2018","journal-title":"Chemistry"},{"key":"10.1016\/j.biopha.2022.114021_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1349-7006.2006.00382.x","article-title":"4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma","volume":"98","author":"Ito","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2022.114021_bib16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/jcm9020318","article-title":"Nanosystems for improved targeted therapies in melanoma","volume":"9","author":"Beiu","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2022.114021_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2217\/nnm-2018-0388","article-title":"Copper complex nanoformulations featuring highly promising therapeutic potential in murine melanoma models","volume":"14","author":"Pinho","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biopha.2022.114021_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1089\/jamp.2011.0928","article-title":"Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats","volume":"25","author":"Gaspar","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.biopha.2022.114021_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2020.02.005","article-title":"Nanotechnology approaches in the current therapy of skin cancer","volume":"153","author":"Borgheti-Cardoso","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2022.114021_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.02.040","article-title":"Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities","volume":"277","author":"Belfiore","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2022.114021_bib21","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.1073\/pnas.88.24.11460","article-title":"Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy","volume":"88","author":"Papahadjopoulos","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.114021_bib22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"80-.","key":"10.1016\/j.biopha.2022.114021_bib23","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: entering the mainstream","volume":"303","author":"Allen","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.114021_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101095","article-title":"GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure","volume":"37","author":"Fonseca","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.biopha.2022.114021_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2019.12.023","article-title":"The role of liposomes in clinical nanomedicine development. What now? Now what?","volume":"318","author":"Crommelin","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2022.114021_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2022.114021_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","article-title":"Liposomes: advancements and innovation in the manufacturing process","volume":"154\u2013155","author":"Shah","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2022.114021_bib28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/nano10020276","article-title":"Nanocarriers as magic bullets in the treatment of leukemia","volume":"10","author":"Houshmand","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.biopha.2022.114021_bib29","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.nano.2015.06.008","article-title":"Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems","volume":"11","author":"Gaspar","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biopha.2022.114021_bib30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/BF02531316","article-title":"Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots","volume":"5","author":"Rouser","year":"1970","journal-title":"Lipids"},{"key":"10.1016\/j.biopha.2022.114021_bib31","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2217\/nnm-2016-0086","article-title":"Nanoformulations of a potent copper-based aquaporin inhibitor with cytotoxic effect against cancer cells","volume":"11","author":"Nave","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biopha.2022.114021_bib32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jconrel.2006.10.018","article-title":"Enzymosomes with surface-exposed superoxide dismutase: in vivo behaviour and therapeutic activity in a model of adjuvant arthritis","volume":"117","author":"Gaspar","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2022.114021_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ctrv.2012.06.002","article-title":"Temozolomide and unusual indications: review of literature","volume":"39","author":"Tatar","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2022.114021_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nantod.2010.03.003","article-title":"Targeted nanodelivery of drugs and diagnostics","volume":"5","author":"Phillips","year":"2010","journal-title":"Nano Today"},{"key":"10.1016\/j.biopha.2022.114021_bib35","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1128\/AAC.44.9.2424-2430.2000","article-title":"Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection","volume":"44","author":"Gaspar","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.114021_bib36","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1023\/A:1012142520912","article-title":"Effect of freezing rate on the stability of liposomes during freeze-drying and rehydration","volume":"14","author":"van Winden","year":"1997","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2022.114021_bib37","unstructured":"Charles River Laboratories, C57BL\/6 Mice, (2012). \u3008https:\/\/www.criver.com\/sites\/default\/files\/resources\/C57BL6MouseClinicalPathologyData.pdf\u3009 (Accessed November 25, 2020)."},{"key":"10.1016\/j.biopha.2022.114021_bib38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(99)00219-6","article-title":"Serum aminotransferase concentration as evidence of hepatocellular damage","volume":"355","author":"Kew","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.114021_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40264-014-0182-7","article-title":"Evolution of the food and drug administration approach to liver safety assessment for new drugs: current status and challenges","volume":"37","author":"Senior","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.biopha.2022.114021_bib40","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3390\/cancers12102893","article-title":"Advances in natural or synthetic nanoparticles for metastatic melanoma therapy and diagnosis","volume":"12","author":"Arasi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2022.114021_bib41","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3389\/fonc.2019.00512","article-title":"The melding of drug screening platforms for melanoma","volume":"9","author":"Couto","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2022.114021_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067911","article-title":"Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging","volume":"8","author":"Viel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.114021_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000345","article-title":"Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma","volume":"8","author":"Saha","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2022.114021_bib44","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.3390\/cancers12103057","article-title":"From conventional therapies to immunotherapy: Melanoma treatment in review","volume":"12","author":"Kuryk","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2022.114021_bib45","series-title":"Drug Deliv. Nanoparticles Formul. Charact.","first-page":"35","article-title":"Formulation of NPDDS for macromolecules","author":"Cruz","year":"2009"},{"key":"10.1016\/j.biopha.2022.114021_bib46","first-page":"271","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000"},{"key":"10.1016\/j.biopha.2022.114021_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/705265","article-title":"Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting","volume":"2013","author":"Perche","year":"2013","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.biopha.2022.114021_bib48","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.nano.2017.02.008","article-title":"Tumor accumulation of liposomal doxorubicin in three murine models: optimizing delivery efficiency","volume":"13","author":"Dawidczyk","year":"2017","journal-title":"Nanomed. Nanotechnol., Biol. Med"},{"key":"10.1016\/j.biopha.2022.114021_bib49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0005-2736(01)00411-4","article-title":"Targeting stealth liposomes in a murine model of human small cell lung cancer","volume":"1515","author":"Moreira","year":"2001","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"key":"10.1016\/j.biopha.2022.114021_bib50","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.biopha.2022.114021_bib51","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.biopha.2022.114021_bib52","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2022.114021_bib53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2022.114021_bib54","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/cmdc.201300248","article-title":"Targets, structures, and recent approaches in malignant melanoma chemotherapy","volume":"8","author":"Matos","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.biopha.2022.114021_bib55","series-title":"Cancer Drug Des. Discov","first-page":"157","article-title":"Temozolomide: from cytotoxic to molecularly-targeted agent","author":"Stevens","year":"2008"},{"key":"10.1016\/j.biopha.2022.114021_bib56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF00688855","article-title":"Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide","volume":"27","author":"Tsang","year":"1991","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2022.114021_bib57","series-title":"Cytochrome P450 Enzym. Biochem. Pharmacol. Heal. Implic.","first-page":"13","article-title":"Cytochrome P450-mediated toxicity of therapeutic drugs","author":"Matias","year":"2014"},{"key":"10.1016\/j.biopha.2022.114021_bib58","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/1534735410391661","article-title":"Exploiting tyrosinase expression and activity in melanocytic tumors","volume":"10","author":"Vargas","year":"2011","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.biopha.2022.114021_bib59","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/0006-2952(87)90501-6","article-title":"Mechanism of selective toxicity of 4-S-cysteinylphenol and 4-S-cysteaminylphenol to melanocytes","volume":"36","author":"Shosuke","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2022.114021_bib60","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/ijc.2910460530","article-title":"The in vivo antimelanoma effect of 4-S-cysteaminylphenol and its N-acetyl derivative","volume":"46","author":"Miura","year":"1990","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2022.114021_bib61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdermsci.2012.04.009","article-title":"N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model","volume":"67","author":"Ishii-Osai","year":"2012","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.biopha.2022.114021_bib62","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4161\/cbt.24348","article-title":"Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers","volume":"14","author":"Vielhauer","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2022.114021_bib63","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.V120.21.1833.1833","article-title":"The DNA methyltransferase inhibitor decitabine induces DNA damage, cell cycle arrest and apoptosis in multiple myeloma","volume":"120","author":"Maes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.114021_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2020.09.018","article-title":"The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib","author":"Wichmann","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2022.114021_bib65","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1046\/j.1523-1747.1999.00781.x","article-title":"Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs","volume":"113","author":"Thomas","year":"1999","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.biopha.2022.114021_bib66","first-page":"1","article-title":"Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy","volume":"2009","author":"Takada","year":"2009","journal-title":"J. Biomed. Biotechnol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222201410X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222201410X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:16:29Z","timestamp":1778242589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222201410X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":66,"alternative-id":["S075333222201410X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114021","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114021"}}